louisiana semaglutide ban US states drop Medicaid coverage of GLP-1 weight-loss drugs as demand rises | US healthcare Louisiana Senate approves weight loss

In the context of weight-loss medication, especially when switching between GLP-1 receptor agonists such as semaglutide (Wegovy) or Tirzepatide (Mounjaro)washout periods are a crucial safety measure

According to Eli Lilly, the randomised, double-blind trial included groups of participants on three different doses 6 mg, 12 mg, and 36 mg as well as a placebo group

This step is done for every trial regardless of the phase they are in, in order to find a group of people who can participate in the trial with minimal variations in the results

Elevating legs when lying down or sleeping

A ketogenic intervention improves dorsal attention network functional and structural connectivity in mild cognitive impairment